Brilacidin
Phase 2Small molecule
Brilacidin is one of 88 small molecule programs targeting Skin Infection. It is currently in Phase 2.
3
Indications
4
Total Trials
0
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Biaxin
AbbViePreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Stivarga
BayerPreclinical
Brilacidin
IInnovation Pharmaceuticals, Inc.
Phase 2
Nitrostat
VViatris Specialty LLC
Preclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
Orap
TevaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-191 trial
Liver1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brilacidin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IInnovation Pharmaceuticals, Inc.